Cancer researchers are one step closer to developing an effective vaccine to treat people with clear cell renal cell ...

In a small clinical trial of nine patients with stage III and IV kidney cancer, a personalized anti-tumor vaccine generated ...

Vaccines generated using the cells left over after tumour removal surgery could help to keep patients from redeveloping ...

A personalized neoantigen cancer vaccine generated strong immune responses in renal cell carcinoma patients, leading to ...

An experimental vaccine for kidney cancer is off to a promising start. In data from a Phase I trial released this week, the ...

After their advanced kidney tumors were surgically removed, nine patients were protected from the cancer returning thanks to ...

Dana-Farber Cancer Institute researchers report that all nine patients in a clinical trial being treated for stage III or IV clear cell renal cell carcinoma (a form of kidney cancer), generated a ...

In a clinical trial, patients treated with a kidney cancer vaccine remained cancer-free after a median of nearly three years.

DelveInsight’s, “Metastatic Colorectal Cancer Pipeline Insight” report provides comprehensive insights about 80+ companies ...

Personalized vaccine targets key driver mutations and induces antitumor immunity in fully resected high-risk clear cell renal cell carcinoma.

Researchers evaluated a neoantigen-targeting personalized cancer vaccine in patients with high-risk, fully resected clear ...

All patients involved in the phase 1 trial of a personalized cancer vaccine for high-risk stage III/IV kidney cancer showed a ...